ArriVent BioPharma, Valuation
| AVBP Stock | 18.98 1.23 6.09% |
At this time, the firm appears to be undervalued. ArriVent BioPharma, shows a prevailing Real Value of USD23.42 per share. The current price of the firm is USD18.98. Our model approximates the value of ArriVent BioPharma, from analyzing the firm fundamentals such as Shares Owned By Insiders of 9.71 %, return on equity of -0.39, and Current Valuation of 468.78 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting ArriVent BioPharma,'s valuation include:
Undervalued
Today
Please note that ArriVent BioPharma,'s price fluctuation is not too volatile at this time. Calculation of the real value of ArriVent BioPharma, is based on 3 months time horizon. Increasing ArriVent BioPharma,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
ArriVent BioPharma,'s intrinsic value may or may not be the same as its current market price of 18.98, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 18.98 | Real 23.42 | Target 38.0 | Hype 18.97 | Naive 19.62 |
The intrinsic value of ArriVent BioPharma,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence ArriVent BioPharma,'s stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of ArriVent BioPharma, Common helps investors to forecast how ArriVent stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ArriVent BioPharma, more accurately as focusing exclusively on ArriVent BioPharma,'s fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use ArriVent BioPharma,'s intrinsic value based on its ongoing forecasts of ArriVent BioPharma,'s financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against ArriVent BioPharma,'s closest peers.
ArriVent BioPharma, Cash |
|
ArriVent Valuation Trend
ArriVent BioPharma,'s real value is important for investors to make better decisions and a more accurate overall view of ArriVent BioPharma,'s financial worth over time. Using both ArriVent BioPharma,'s enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
ArriVent Valuation Data Drivers
ArriVent BioPharma, Total Value Analysis
ArriVent BioPharma, Common is presently forecasted to have valuation of 468.78 M with market capitalization of 687.47 M, debt of 176 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the ArriVent BioPharma, fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
468.78 M | 687.47 M | 176 K |
ArriVent BioPharma, Asset Utilization
One of the ways to look at asset utilization of ArriVent is to check how much profit was generated for every dollar of assets it reports. ArriVent BioPharma, Common shows a negative utilization of assets of -0.27 percent, losing USD0.002691 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of ArriVent BioPharma, Common shows how discouraging it operates for each dollar spent on its assets.ArriVent BioPharma, Ownership Allocation
ArriVent BioPharma, holds a total of 34.02 Million outstanding shares. The majority of ArriVent BioPharma, Common outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in ArriVent BioPharma, to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in ArriVent BioPharma,. Please pay attention to any change in the institutional holdings of ArriVent BioPharma, Common as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.ArriVent BioPharma, Profitability Analysis
Net Loss for the year was (80.49 M) with profit before overhead, payroll, taxes, and interest of 0.About ArriVent BioPharma, Valuation
The stock valuation mechanism determines ArriVent BioPharma,'s current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of ArriVent BioPharma, based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of ArriVent BioPharma,. We calculate exposure to ArriVent BioPharma,'s market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ArriVent BioPharma,'s related companies.ArriVent BioPharma, Growth Indicators
Investing in growth stocks can be very risky. If the company such as ArriVent BioPharma, does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 33.7 M |
ArriVent BioPharma, Current Valuation Indicators
ArriVent BioPharma,'s valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final ArriVent BioPharma,'s valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as ArriVent BioPharma,, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use ArriVent BioPharma,'s valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes ArriVent BioPharma,'s worth.Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.